SCD and metabolic dysfunction-associated steatotic liver disease: Our results imply that: (i) the expression and activity of scd-1 promotes the effects of caffeine; (ii) these effects may be related to its plasma-glucose lowering and anti-NAFLD actions; (iii) caffeine may potent treatment for these effects.